Frank Hoentjen
Radboud University Nijmegen
Internal medicineRetrospective cohort studyTumor necrosis factor alphaProspective cohort studyAdverse effectCohort studyVedolizumabInfliximabInflammatory bowel diseaseDiscontinuationUstekinumabDiseaseCrohn's diseaseAdalimumabUlcerative colitisPopulationIn patientThiopurine methyltransferaseMedicineCohortGastroenterology
Publications 174
Last. Marie J. PierikH-Index: 25
view all 16 authors...
#1Maxine D. Rouvroye (VU: VU University Amsterdam)H-Index: 2
#2Greetje J. TackH-Index: 6
Last. A.A. van BodegravenH-Index: 28
view all 37 authors...
Abstract Immunosuppressive drugs are the cornerstone in the treatment of inflammatory bowel disease (IBD), however they are associated with an increased risk of extra-intestinal cancer. Whether the risk for female genital tract malignancies, including vulvar and vaginal cancer, is increased is less clear. Our aim was to investigate the risk of these malignancies in IBD-patients. Histopathological data of all IBD patients with a vulvar or vaginal (pre-)cancerous lesion were retrieved from the Dut...
2 CitationsSource
#1Pepijn W. A. Thomas (Radboud University Nijmegen)H-Index: 1
#2Rachel WestH-Index: 6
Last. Frank Hoentjen (Radboud University Nijmegen)H-Index: 16
view all 8 authors...
1 CitationsSource
#1Biemans drs (Radboud University Nijmegen Medical Centre)H-Index: 1
#1V Biemans drs (Radboud University Nijmegen Medical Centre)
Last. Marie J. Pierik (Maastricht University Medical Centre)H-Index: 25
view all 17 authors...
1 CitationsSource
#1M de Jong (Radboud University Nijmegen)H-Index: 1
#2S Vos (Radboud University Nijmegen)
Last. Frank Hoentjen (Radboud University Nijmegen)H-Index: 16
view all 6 authors...
#1Vera E R Asscher (LUMC: Leiden University Medical Center)H-Index: 2
#2Vince B. C. Biemans (Radboud University Nijmegen)H-Index: 6
Last. J Maljaars (LUMC: Leiden University Medical Center)H-Index: 1
view all 17 authors...
#1Vince B. C. Biemans (UM: Maastricht University)H-Index: 2
#2Edo SavelkoulH-Index: 2
Last. Frank Hoentjen (Radboud University Nijmegen)H-Index: 16
view all 9 authors...
#1Uri Kopylov (Sheba Medical Center)H-Index: 46
#2Jurij HanzelH-Index: 5
Last. David DrobneH-Index: 5
view all 34 authors...
1 CitationsSource
#1Michiel E. de Jong (Radboud University Nijmegen)H-Index: 3
#2Heleen Kanne (Radboud University Nijmegen)H-Index: 1
Last. Frank Hoentjen (Radboud University Nijmegen)H-Index: 16
view all 6 authors...
Abstract Background and Aims The impact of recurrent low-grade dysplasia (LGD) on the risk of advanced neoplasia (high-grade dysplasia and colorectal cancer) in inflammatory bowel disease (IBD) patients is unknown. In addition, it is unclear how a neoplasia-free period after index LGD impacts this risk. We aimed (1) to determine whether recurrent LGD is a risk factor for advanced neoplasia development and (2) to evaluate the impact of a neoplasia-free time period after initial LGD diagnosis on t...
4 CitationsSource
#1Annick Moens (Katholieke Universiteit Leuven)H-Index: 6
Last. Marc Ferrante (Katholieke Universiteit Leuven)H-Index: 59
view all 25 authors...
BACKGROUND: Women with inflammatory bowel diseases (IBD) often receive biologicals during pregnancy to maintain disease remission. Data on outcome of vedolizumab-exposed pregnancies (VDZE) are sparse. AIMS: To assess pregnancy and child outcomes of VDZE pregnancies and to compare these results to anti-TNF exposed (TNFE) or both immunomodulatory and biologic unexposed (CON IBD) pregnancies. METHODS: A retrospective multicentre case-control observational study was performed. RESULTS: VDZE group in...
28 CitationsSource